143 related articles for article (PubMed ID: 22933147)
1. A reinterpretation of the pathogenesis and cure of cancer according to the psychoneuroimmunological discoveries.
Lissoni P
Methods Mol Biol; 2012; 934():183-92. PubMed ID: 22933147
[TBL] [Abstract][Full Text] [Related]
2. Principles of psychoneuroendocrinoimmunotherapy of cancer.
Lissoni P; Rovelli F
Immunotherapy; 2012 Jan; 4(1):77-86. PubMed ID: 22150002
[TBL] [Abstract][Full Text] [Related]
3. How to Monitor the Neuroimmune Biological Response in Patients Affected by Immune Alteration-Related Systemic Diseases.
Lissoni P; Rovelli F; Vigorè L; Messina G; Lissoni A; Porro G; Di Fede G
Methods Mol Biol; 2018; 1781():171-191. PubMed ID: 29705848
[TBL] [Abstract][Full Text] [Related]
4. Cortisol response to an acute injection of IL-2 in healthy subjects and cancer patients: a first immunoneuroendocrine standardized clinical test to explore the interactions between immune and neuroendocrine systems.
Lissoni P; Messina G; Brivio F; Rovelli F; Di Fede G; Mainini E; Veronese E
J Biol Regul Homeost Agents; 2005; 19(3-4):141-4. PubMed ID: 16602629
[TBL] [Abstract][Full Text] [Related]
5. Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin.
Lissoni P; Fumagalli L; Paolorossi F; Rovelli F; Roselli MG; Maestroni GJ
J Biol Regul Homeost Agents; 1997; 11(3):119-22. PubMed ID: 9498162
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2, melatonin and interleukin-12 as a possible neuroimmune combination in the biotherapy of cancer.
Lissoni P; Pittalis S; Rovelli F; Vigorè L; Roselli MG; Brivio F
J Biol Regul Homeost Agents; 1995; 9(2):63-6. PubMed ID: 9127635
[TBL] [Abstract][Full Text] [Related]
7. Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms.
Lissoni P
Ann N Y Acad Sci; 2000; 917():560-7. PubMed ID: 11268384
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory effects of IL-12 in relation to the pineal endocrine function in metastatic cancer patients.
Lissoni P; Rovelli F; Giani L; Fumagalli L; Mandalà M
Nat Immun; 1998; 16(5-6):178-84. PubMed ID: 11061586
[TBL] [Abstract][Full Text] [Related]
9. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors.
Lissoni P; Brivio F; Fumagalli L; Messina G; Vigoré L; Parolini D; Colciago M; Rovelli F
Anticancer Res; 2008; 28(2B):1377-81. PubMed ID: 18505083
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
Lissoni P; Bolis S; Brivio F; Fumagalli L
Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160
[TBL] [Abstract][Full Text] [Related]
11. The immune-pineal axis: a shuttle between endocrine and paracrine melatonin sources.
Markus RP; Ferreira ZS; Fernandes PA; Cecon E
Neuroimmunomodulation; 2007; 14(3-4):126-33. PubMed ID: 18073503
[TBL] [Abstract][Full Text] [Related]
12. A new neuroimmunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone.
Lissoni P; Malugani F; Bordin V; Conti A; Maestroni G; Tancini G
Neuro Endocrinol Lett; 2002 Jun; 23(3):255-8. PubMed ID: 12080288
[TBL] [Abstract][Full Text] [Related]
13. Oncostatic activity of pineal neuroendocrine treatment with the pineal indoles melatonin and 5-methoxytryptamine in untreatable metastatic cancer patients progressing on melatonin alone.
Lissoni P; Rovelli F; Frassineti A; Fumagalli L; Malysheva O; Conti A; Maestroni G
Neuro Endocrinol Lett; 2000; 21(4):319-323. PubMed ID: 11455367
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory properties of a pineal indole hormone other than melatonin, the 5-methoxytryptophol.
Lissoni P; Pittalis S; Rovelli F; Zecchini S; Casati M; Tremolada M; Pelizzoni F
J Biol Regul Homeost Agents; 1996; 10(1):27-30. PubMed ID: 9049779
[TBL] [Abstract][Full Text] [Related]
15. Psychooncology and cancer progression-related alterations of pleasure-associated neurochemical system: Abnormal neuroendocrine response to apomorphine in advanced cancer patients.
Lissoni P; Malugani F; Manganini V; Ardizzoia A; Gardani G; Bartolacelli E; Messina G; Tancini G
Neuro Endocrinol Lett; 2003; 24(1-2):50-3. PubMed ID: 12743532
[TBL] [Abstract][Full Text] [Related]
16. Immune and endocrine mechanisms of advanced cancer-related hypercortisolemia.
Lissoni P; Brivio F; Fumagalli L; Messina G; Secreto G; Romelli B; Fumagalli G; Rovelli F; Colciago M; Brera G
In Vivo; 2007; 21(4):647-50. PubMed ID: 17708360
[TBL] [Abstract][Full Text] [Related]
17. The psychoneuroendocrine-immunotherapy of cancer: Historical evolution and clinical results.
Lissoni P; Messina G; Lissoni A; Franco R
J Res Med Sci; 2017; 22():45. PubMed ID: 28567065
[TBL] [Abstract][Full Text] [Related]
18. A psychoncological study of lymphocyte subpopulations in relation to pleasure-related neurobiochemistry and sexual and spiritual profile to Rorschach's test in early or advanced cancer patients.
Messina G; Lissoni P; Bartolacelli E; Tancini G; Villa S; Gardani GS; Brivio F
J Biol Regul Homeost Agents; 2003; 17(4):322-6. PubMed ID: 15065761
[TBL] [Abstract][Full Text] [Related]
19. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
Lissoni P; Malugani F; Malysheva O; Kozlov V; Laudon M; Conti A; Maestroni G
Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238
[TBL] [Abstract][Full Text] [Related]
20. Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patients.
Lissoni P; Brivio F; Fumagalli L; Messina G; Meregalli S; Porro G; Rovelli F; Vigorè L; Tisi E; D'Amico G
Anticancer Res; 2009 May; 29(5):1847-52. PubMed ID: 19443415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
